Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Table 3 Adverse events

	SRS and Ipilimumab (n = 45)		SRS and Nivolumab (n = 35)
	Grade 1 or 2	Grade 3	Grade 1 or 2	Grade 3
Number of patients with at least an adverse event^a	31 (68%)	11 (24%)	20 (57%)	6 (17%)
Event
Diarrhoea	11 (24%)	3 (7%)	5 (14%)	1 (3%)
Nausea or vomiting	8 (18%)	1 (2%)	4 (12%)	1 (3%)
Constipation	5 (11%)	0	2 (6%)	0
Increased AST and/or ALT levels	4 (9%)	2 (4%)	4 (12%)	2 (6%)
Fatigue	12 (27%)	3 (7%)	6 (18%)	2 (6%)
Endocrine immune disorders	3 (7%)	0	2 (6%)	0
Rash/Pruritus	10 (22%)	1 (2%)	6 (18%)	1 (3%)
Arthralgia	5 (11%)	0	3 (9%)	0
Muscle weakness right or left sided	3 (7%)	1 (2%)	2 (6%)	1 (3%)
CNS event
Headache	8 (18%)	2 (4%)	4 (12%)	1 (3%)
Hemorrhage	3 (7%)	1 (2%)	2 (6%)	1 (3%)
Seizure	3 (7%)	2 (4%)	2 (6%)	1 (3%)
Diziness	4 (9%)	0	2 (6%)	0
Brain necrosis	13 (29%)	5 (11%)	7 (20%)	3 (9%)
Discontinuation of treatment	5		3

^aTreatment-related adverse events of any grade occurring in at least 5% of patiens in either cohorts. Some patients had more than one event. No grade 4 events were reported in both cohorts